As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aquestive Therapeutics, Inc. The largest reported stake is Bass Edward P's, at 7.5%. 5 filings are on record since October 17, 2025 (Schedule 13G, October 7, 2026).
Sell to companies like Aquestive Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Bass Edward P · Percent: 7.5% · Shares: 9,385,561 · SCHEDULE 13G
- · Holder: Bratton Douglas K · Percent: 0.6% · Shares: 691,873 · SCHEDULE 13G/A
- · Reporting person: BlackRock, Inc. · Sole voting: 7,885,637 · Shared voting: 0 · Sole dispositive: 7,992,647 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Reporting person: RTW Investments, LP · Sole voting: 0 · Shared voting: 6,250,000 · Sole dispositive: 0 · Shared dispositive: 6,250,000 · SCHEDULE 13G, 2025-11-14
- · Holder: BlackRock, Inc. · Percent: 5.3% · SCHEDULE 13G/A
Aquestive Therapeutics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-10-17. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 7.5% | 9,385,561 | SCHEDULE 13G, 2026-10-07 | 2026-10-07 | |
| BlackRock, Inc. | 6.4% | 7,992,647 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
| RTW Investments, LP | 5.2% | 6,250,000 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| 0.6% | 691,873 | SCHEDULE 13G/A, 2026-10-07 | 2026-10-07 |
Holding shares or following this stake? See who's behind Aquestive Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Aquestive Therapeutics, Inc. and the records around it.
Aquestive Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Aquestive Therapeutics, Inc.
Get an email when Aquestive Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aquestive Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aquestive Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aquestive Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Bass Edward P | 9,385,561 | 0 | 9,385,561 | 0 | SCHEDULE 13G, 2026-10-07 |
| Thru Line L.P. | 7,876,267 | 0 | 7,876,267 | 0 | SCHEDULE 13G, 2026-10-07 |
| BlackRock, Inc. | 7,885,637 | 0 | 7,992,647 | 0 | SCHEDULE 13G/A, 2026-07-27 |
| RTW Investments, LP | 0 | 6,250,000 | 0 | 6,250,000 | SCHEDULE 13G, 2025-11-14 |
| Roderick Wong | 0 | 6,250,000 | 0 | 6,250,000 | SCHEDULE 13G, 2025-11-14 |
| Bratton Douglas K | 637,823 | 0 | 637,823 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| MonoLine RX II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| MonoLine RX III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| MonoLine RX, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| MonoLine Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| MonoSol Rx Genpar, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Bratton Capital Management, L.P. | 390,795 | 0 | 390,795 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Bratton Capital Inc. | 391,670 | 0 | 391,670 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Bratton Family Partners L.P. | 33,727 | 0 | 33,727 | 0 | SCHEDULE 13G/A, 2026-10-07 |
The latest filing identifies Aquestive Therapeutics, Inc. by CUSIP 03843E104 and gives its principal executive office as 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ 07059 (SCHEDULE 13G, 2026-10-07).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-17 | BlackRock, Inc. | 5.3% | SCHEDULE 13G/A |
| 2025-11-14 | RTW Investments, LP | 5.2% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 6.4% | SCHEDULE 13G/A |
| 2026-10-07 | Bratton Douglas K | 0.6% | SCHEDULE 13G/A |
| 2026-10-07 | Bass Edward P | 7.5% | SCHEDULE 13G |
Questions about who owns Aquestive Therapeutics, Inc.
Who owns Aquestive Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Aquestive Therapeutics, Inc.: Bass Edward P (7.5%, Schedule 13G, filed 2026-10-07), BlackRock, Inc. (6.4%, Schedule 13G/A, filed 2026-07-27) and RTW Investments, LP (5.2%, Schedule 13G, filed 2025-11-14).
Who are the largest shareholders of Aquestive Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aquestive Therapeutics, Inc. on this page are Bass Edward P (7.5%), BlackRock, Inc. (6.4%) and RTW Investments, LP (5.2%).
When did Bass Edward P buy into Aquestive Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bass Edward P on this page is the Schedule 13G, filed 2026-10-07, reporting 7.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aquestive Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 29, 2026 | Leadership change: Richard J. Daly appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Aquestive Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.